Difference between revisions of "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France"
(formatting) |
|||
| Line 8: | Line 8: | ||
* Jean-Christophe Lagier | * Jean-Christophe Lagier | ||
* Philippe Gautret | * Philippe Gautret | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
*... | *... | ||
* Didier Raoult | * Didier Raoult | ||
Latest revision as of 03:09, 22 July 2020
| Publication | |
| Title | |
| Authors |
|
| Journal | Travel Med Infect Dis |
| Date | May 5, 2020 |
Observational, non-comparative study of 1061 COVID-19 patients treated early with hydroxychloroquine and azithromycin in Marseille resulted in 91.7% virologically cure-rate within 10 days.
Mortality rate in the total cohort was 0.75%, lower than the mortality rates in other neighboring Marseille public hospitals (p < 0.01). The mean time between symptom onset and treatment was 6.4 days. This study was one of the first to assess efficacy of early treatment with hydroxychloroquine and azithromycin in hospitalized patients.
Major Issues
Without a control group within the IHU, this study relied on comparison to mortality rates in other hospitals in Marseille. This is problematic, however, as the IHU admits COVID-19 patients for treatment even if patients have only mild symptoms or are asymptomatic. This differs from other hospitals in Marseille where admitted patients tend to be sicker or with greater proportion of negative prognostic indicators.
Minor Issues
No minor issues identified at this time.
Impact
This was one of the first studies assessing efficacy of early treatment with hydroxychloroquine and azithromycin in hospitalized COVID-19 patients.
Article Revisions
None at this time.